In Vitro Competitive Metabolism Study of Olmesartan Medoxomil in Rat Liver S9 Fractions Using LC/MS
Copyright © 2011 SciRes. PP
374
Table 1. Relative percentage Olmesartan formation.
Relative Percentage of Olmesartan Formation
Drug
0 min % RSD 30 min % RSD 60 min %RSD
OLM 5.61 4.200 67.44 5.241 95.04 4.391
OLM + FEN 6.39 3.547 63.96 3.652 88.48 5.330
OLM + RPL 10.67 2.846 65.38 2.845 82.36 4.788
OLM + RPL + FEN 7.55 4.529 59.42 3.139 76.08 4.221
drugs; hence combination or co-administration of such
drugs could be avoided.
REFERENCES
[1] N. Sultana, M. S. Arayane, S. S Ali and S. Sajid, “Simul-
taneous Determination of Olmesartan Medoxomil and Ir-
besartan and Hydrochlorothiazide in Pharmaceutical For-
mulations and Human Serum Using High Performance
Liquid Chromatography,” Chinese Journal of Chroma-
tography, Vol. 26, No. 5, 2008, pp. 544-549.
doi:10.1016/S1872-2059(08)60029-2
[2] B. Lisiane, R. C. Rochele, D. L. Carolina B. M. Ana and
F. E. Pedro, “Stability-Indicating LC Determination of a
New Antihypertensive, Olmesartan Medoxomil in Tab-
lets,” Chromatographia, Vol. 68, No. 11-12, 2008, pp.
991-996. doi:10.1365/s10337-008-0811-3
[3] P. D. Bari and A. Rote, “RP-LC and HPTLC Methods for
the Determination of Olmesartan Medoxomil and Hydro-
chlorothiazide in Combined Tablet Dosage Forms,” Chro-
matographia, Vol. 69, No. 11-12, 2009, pp. 1469-1472.
doi:10.1365/s10337-009-1094-z
[4] S. G. Chrysant, “Amlodipine Besylate/Olmesartan Me-
doximil Fixed Combination for the Treatment of Hyper-
tension,” Expert Review of Cardiovascular Therapy, Vol.
7, No. 8, 2009, pp. 887-895. doi:10.1586/erc.09.85
[5] D. Liua, P. Hu, N. Matsushima, X. Lia, L. Lia and J. Ji,
“Quantitative Determination of Olmesartan in Human
Plasma and Urine by liquid Chromatography Coupled to
Tandem Mass Spectrometry,” Journal of Chromatogra-
phy B, Vol. 856, No. 1-2, 2007, pp. 190-197.
doi:10.1016/j.jchromb.2007.05.049
[6] B. Yuan, X. Wang, F. Zhang, J. Jia and F. Tang, “Simul-
taneous Determination of Ramipril and Its Active Me-
tabolite Ramiprilat in Human Plasma by LC-MS-MS,”
Chromatographia, Vol. 68, No. 7-8, 2008, pp. 533-539.
doi:10.1365/s10337-008-0757-5
[7] B.-A. Persson, C. Fakt, M. Ervik and M. Ahnoff, “Inter-
ference from a Glucuronide Metabolite in the Determina-
tion of Ramipril and Ramiprilat in Human Plasma and
Urine by Gas Chromatography-Mass Spectrometry,” Jour-
nal of Pharmaceutical and Biomedical Analysis, Vol. 40,
No. 3, 2006, pp. 794-797.
[8] X.-Y. Lu, J.-Z. Shen-Tu and J. Liu, “High-Performance
Liquid Chromatography-Mass Spectrometric Analysis of
Ramipril and Its Active Metabolite Ramiprilat in Human
Serum: Application to a Pharmacokinetic Study in the
Chinese Volunteers,” Journal of Pharmaceutical and Bio-
medical Analysis, Vol. 40, No. 2, 2006, pp. 478-483.
doi:10.1016/j.jpba.2005.07.054
[9] Z. Zhimeng, “Liquid Chromatography-Mass Spectrome-
try Method for Determination of Ramipril and Its Active
Metabolite Ramiprilat in Human Plasma,” Journal of
Chromatography B, Vol. 779, No. 2, 2002, pp. 297-306.
doi:10.1016/S1570-0232(02)00398-7
[10] G. E. Linda, “Evaluation of the Potential for Pharma-
cokinetic Interaction between Fenofibrate and Ezetimibe:
A Phase I, Open-Label, Multiple-Dose, Three-Period
Crossover Study in Healthy Subjects,” Clinical Thera-
peutics, Vol. 28, No. 3, 2006, pp. 373-387.
doi:10.1016/j.clinthera.2006.03.009
[11] Z. Zhu, A. Vachareau and L. Neirinck, “Liquid Chroma-
tography-Mass Spectrometry Method for Determination
of Ramipril and Its Active Metabolite Ramiprilat in Hu-
man Plasma,” Journal of Chromatography B, Vol. 779,
No. 2, 2002, pp. 297-306.
doi:10.1016/S1570-0232(02)00398-7
[12] V. P. Chintan, P. K. Amit, D. C. Anandi and T. P. Kal-
pesh, “Validated Absorption Factor Spectrophotometric
and Reversed-Phase High-Performance Liquid Chroma-
tographic Methods for the Determination of Ramipril and
Olmesartan Medoxomil in Pharmaceutical Formulations,”
Eurasian Journal of Analytical Chemistry, Vol. 2, No. 3,
2007, pp. 159-171.